Contents

Molecular Cancer Therapeutics
The Journal of Cancer Drug Discovery & Preclinical Development
November 2013 • Volume 12 • Number 11

LARGE MOLECULE THERAPEUTICS

CANCER THERAPEUTICS INSIGHTS

TOOLS AND TECHNOLOGIES

LETTER TO THE EDITOR

AC icon indicates Author Choice

For more information please visit www.aacrjournals.org

ABOUT THE COVER

Ribbon representation of a homology model of the c-Met specific Anticalin PRS-110. Anticalins are engineered human lipocalins that represent a next generation class of drug molecules. The lipocalins have a structurally conserved β-barrel architecture that forms a cup-shaped ligand binding pocket that can accommodate small and large ligands. The β strands (blue) of the lipocalin form the base of the ligand-binding pocket and the entry of the pocket is comprised of four loops connecting the β strands. Novel, target-specific Anticalins are generated by engineering mutations (pink regions, PRS-110 mutations) within these four loops and then selecting variants with the desired binding activity. For details, see article by Olwill and colleagues on page 2459.



Molecular Cancer Therapeutics

12 (11)

Mol Cancer Ther 2013;12:2283-2615.